SCHEMBL1804240

SCHEMBL1804240

Cc1cc(-c2ccc3c(c2)C(=O)NC[C@@H]2CN(C)C[C@@H]32)ccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.47
CLK4 Q9HAZ1 2/20 0.47
DAPK3 O43293 1/20 0.47
NTRK1 P04629 1/20 0.47
FLT3 P36888 1/20 0.47
GSK3B P49841 1/20 0.47
ROCK1 Q13464 1/20 0.47
PIM2 Q9P1W9 1/20 0.36
GRM5 P41594 1/20 0.34
GRIN1 Q05586 4/20 0.33
GRIN2B Q13224 4/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
FYN P06241 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
CA12 O43570 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
GRIA2 P42262 1/20 0.32
PDE3B Q13370 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1804237 1.00 PIM1 (0.47) PIM1CLK4DAPK3NTRK1FLT3
SCHEMBL1804241 1.00 PIM1 (0.47) PIM1CLK4DAPK3NTRK1FLT3
SCHEMBL2599078 0.91 PIM1 (0.36) PIM1CLK4DAPK3NTRK1FLT3
SCHEMBL860932 0.91 PIM1 (0.36) PIM1CLK4DAPK3NTRK1FLT3
SCHEMBL2599076 0.91 PIM1 (0.36) PIM1CLK4DAPK3NTRK1FLT3
SCHEMBL1805029 0.91 PIM1 (0.36) PIM1CLK4DAPK3NTRK1FLT3
SCHEMBL1804970 0.88 CLK4 (0.33) PIM1CLK4DAPK3NTRK1FLT3
SCHEMBL1804967 0.88 CLK4 (0.33) PIM1CLK4DAPK3NTRK1FLT3
SCHEMBL1804971 0.88 CLK4 (0.33) PIM1CLK4DAPK3NTRK1FLT3
SCHEMBL861567 0.87 HRH3 (0.38) PIM1CLK4MEN1KMT2AFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571353-B1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC (US) 2017-08-09 EP claimed
US-20110118231-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-05-19 US claimed
EP-2571353-B1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC (US) 2017-08-09 EP disclosed
US-8846951-B2 Modulators of 5-HT receptors and methods of use thereof ABBVIE INC. (US) 2014-09-30 US disclosed
US-20110118231-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118231-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C PIM1 4508/4885CLK4 3097/4885DAPK3 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.